Brokerages Set Pyxis Oncology, Inc. (NASDAQ:PYXS) PT at $7.25

Pyxis Oncology, Inc. (NASDAQ:PYXS) has received a consensus recommendation of “Hold” from the seven research firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $7.25.

PYXS has been the topic of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pyxis Oncology in a research report on Wednesday, October 8th. HC Wainwright restated a “buy” rating and issued a $5.00 price objective on shares of Pyxis Oncology in a report on Tuesday, August 19th. Zacks Research cut Pyxis Oncology from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 4th. Stifel Nicolaus started coverage on shares of Pyxis Oncology in a report on Monday, November 3rd. They issued a “buy” rating and a $9.00 price target on the stock. Finally, Guggenheim lifted their price target on shares of Pyxis Oncology from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th.

Pyxis Oncology Price Performance

PYXS opened at $4.36 on Thursday. Pyxis Oncology has a 12 month low of $0.83 and a 12 month high of $4.80. The business has a 50-day moving average of $3.03 and a two-hundred day moving average of $1.84. The stock has a market capitalization of $271.45 million, a price-to-earnings ratio of -2.72 and a beta of 1.41.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.01. Equities research analysts anticipate that Pyxis Oncology will post -1.04 earnings per share for the current year.

Institutional Investors Weigh In On Pyxis Oncology

Several institutional investors and hedge funds have recently modified their holdings of PYXS. Longaeva Partners L.P. purchased a new stake in shares of Pyxis Oncology during the 3rd quarter valued at about $1,117,000. Jane Street Group LLC purchased a new stake in shares of Pyxis Oncology during the second quarter valued at approximately $370,000. Pier 88 Investment Partners LLC raised its stake in shares of Pyxis Oncology by 296.6% during the first quarter. Pier 88 Investment Partners LLC now owns 390,960 shares of the company’s stock valued at $383,000 after purchasing an additional 292,370 shares during the period. Schulhoff & Co. Inc. lifted its position in shares of Pyxis Oncology by 125.4% during the second quarter. Schulhoff & Co. Inc. now owns 275,000 shares of the company’s stock worth $302,000 after purchasing an additional 153,000 shares in the last quarter. Finally, Marshall Wace LLP purchased a new position in shares of Pyxis Oncology in the second quarter valued at $163,000. Hedge funds and other institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.